Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline
Cash Balance: Approximately $103.7 million as of March 31, 2025.
Revenue: Approximately $2.3 million for Q1 2025, compared to $2.6 million in Q1 2024.
R&D Expenses: Approximately $5.8 million for Q1 2025, compared to $6.4 million in Q1 2024.
G&A Expenses: Approximately $2.4 million for both Q1 2025 and Q1 2024.
Net Loss: Approximately $7.2 million or $0.08 per share for Q1 2025, compared to $7.3 million or $0.08 per share in Q1 2024.
Cash Runway: Expected to fund operating plans into 2027.
Warning! GuruFocus has detected 3 Warning Signs with CGEN.
Release Date: May 19, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Compugen Ltd (NASDAQ:CGEN) has initiated a sub-trial for their anti-PVRIG antibody COM701 in ovarian cancer, targeting an unmet medical need.
The company has a strong cash position with a runway extending into 2027, supporting their clinical and research activities.
Compugen Ltd (NASDAQ:CGEN) is advancing its early-stage and clinical immuno-oncology pipeline, focusing on innovative therapies.
Partnership with AstraZeneca is progressing, with multiple Phase 3 trials initiated, potentially leading to significant revenue opportunities.
The company is exploring novel mechanisms of action in their early-stage pipeline, aiming to enhance anticancer immunity.
Revenues for the first quarter of 2025 decreased compared to the same period in 2024.
The company reported a net loss of approximately $7.2 million for the first quarter of 2025.
There is uncertainty in the TIGIT landscape, with previous Phase 3 failures impacting market sentiment.
The success of Compugen Ltd (NASDAQ:CGEN)'s TIGIT program is contingent on positive outcomes from upcoming Phase 3 trials.
The competitive landscape in ovarian cancer is evolving, with new therapies potentially impacting Compugen Ltd (NASDAQ:CGEN)'s strategy.
Q: Merck's KEYNOTE-B96 Phase 3 study in pembrolizumab for platinum-resistant ovarian cancer was successful. How might this impact your strategy in ovarian cancer? A: Michelle Mahler, Chief Medical Officer: The study is in a different setting, but it shows benefit from adding an immune checkpoint inhibitor. If our study demonstrates activity, it could open opportunities to combine COM701 in broader populations.
Q: What is your interpretation of Roche's SKYCRAPER-01 data, and how does it affect your confidence in TIGIT antagonism? A: Eran Ophir, Vice President - Research, Drug Discovery: Despite the failure, we see numerical activity in TIGIT trials. The Fc active format may have contributed to high discontinuation rates. We believe Fc inactive antibodies, like ours, may offer safety and efficacy advantages.
Q: Do you plan to collect data on tumor microenvironment features in the COM701 study? What PFS benefit would be clinically meaningful in the maintenance setting? A: Michelle Mahler, Chief Medical Officer: We will collect data on the tumor microenvironment but won't disclose details. An improvement of around three months in progression-free survival would be clinically meaningful.
Q: Have you observed activity of COM701 in PD-L1 positive patients, and what are your thoughts on PD-1 VEGF bispecifics? A: Michelle Mahler, Chief Medical Officer: We see activity in both PD-L1 positive and negative patients. Eran Ophir, Vice President - Research, Drug Discovery: VEGF increases T cell infiltration, complementing PVRIG biology. Fc inactive TIGIT may be preferable for combinations due to safety concerns.
Q: What are your thoughts on the potential synergy between TIGIT, PD-1, and VEGF inhibitors? A: Eran Ophir, Vice President - Research, Drug Discovery: VEGF can enhance T cell infiltration, aligning with PVRIG biology. While we haven't published data, combining with Fc inactive TIGIT could be advantageous due to safety profiles.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
China Just Froze a $35 Billion U.S. Merger -- And Investors Should Pay Attention
The $35 billion merger between Synopsys (SNPS) and Ansys has hit a significant roadblock as China's antitrust regulator postponed its final approval following renewed U.S. export controls. The proposed tie-up, which had already advanced to the final review stage by China's State Administration for Market Regulation, now faces uncertainty after the Trump administration expanded restrictions on semiconductor design software and other sensitive technologies to China. According to sources cited by the Financial Times, the delay is directly tied to Washington's latest move in late May to restrict sales of chip design toolsaffecting companies like Synopsyswithout special licenses. Warning! GuruFocus has detected 3 Warning Sign with GME. The timing of the setback comes just days after U.S. and Chinese officials reached a tentative truce in London to ease broader trade friction. However, the agreement appears fragile, with Beijing's curbs on critical mineral exports triggering further U.S. clampdowns. As a result, licenses for certain suppliers have been revoked, and a broader licensing regime has been reinstated. For Synopsys and Ansys, these geopolitical shifts now threaten to derail a merger that had already cleared regulatory hurdles in all other jurisdictions except China. Neither company, nor the Chinese regulator, has publicly commented on the reported delay. On the domestic front, the U.S. Federal Trade Commission last month required the divestiture of certain assets to alleviate antitrust concerns tied to the deal. Synopsys CEO has indicated that regulatory approval has been secured globallywith China as the sole outlier. Investors are watching closely as the delay could stretch the closing timeline or possibly trigger renegotiation risks, especially if trade tensions escalate further. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 days ago
- Yahoo
5 top FTSE 100 stocks offering plenty of global growth for an ISA
The FTSE 100 is made up of the largest companies listed in London. But this doesn't mean that most stocks are UK-focused, far from it. In fact, it's quite straightforward to build a Stocks and Shares ISA portfolio of FTSE 100 shares that offer truly global exposure. Here are five that would certainly do the job. Let's start with the largest stock by market cap in the Footsie today: AstraZeneca (LSE: AZN). This healthcare giant has truly global operations, spanning the areas of oncology, respiratory and immunology, rare diseases, and more. This year, the firm is expected to rake in $57.5bn in revenue, with a net profit of about $14bn. And it generates this from nearly everywhere, including China and Japan. Region % of total revenue (2024) US 40% Europe 16% China 12% UK 9% Japan 6% Rest of world 17% As we can see, investors in AstraZeneca are getting diversified exposure to the whole of the developed world. The reason the US is such a sizeable part is because it has the largest healthcare system of them all. The stock has fallen 17.5% since the end of August, putting it on a forward price-to-earnings (P/E) ratio of 15.5. For a profitable firm of this calibre, which also offers a 2.3% dividend yield, I think that's very attractive. Turning to another FTSE 100 giant now, we have HSBC (LSE: HSBA). The bank is increasingly focused on Asia these days, as that's where most of the world's growth is expected to come from in future. Indeed, according to the Asian Development Bank, Asia's middle class is set to swell to roughly 3bn people by 2050. With HSBC increasingly focused on wealth management in the region, the long-term growth story looks very promising. This year, the bank is expected to earn around $23bn on revenue of almost $67bn. The stock is offering an attractive 5.8% dividend yield. The third stock is Airtel Africa. As the name implies, the firm's operations extend across Africa. Specifically, Airtel is a provider of telecommunications and mobile money services to 166m people in 14 countries in sub-Saharan Africa. The share price has been on a tear, surging 55% this year alone. However, it still looks decent value to me, trading at 12.5 times next year's forecast earnings. There's also a well-supported 2.8% dividend yield. Finally, for even more global portfolio exposure, investors could consider Coca Cola HBC and Coca-Cola Europacific Partners. These are both bottling partners for the US beverage giant, selling brands like Coca-Cola, Fanta, Sprite, and Monster. The former's markets include Western Europe and the Asia-Pacific region, including Australia, New Zealand, and the Philippines. The other's portfolio is more weighted toward emerging and developing markets, including Poland, Romania, Nigeria, and Egypt. Naturally, none of these five stocks are totally risk-free. The Coca-Cola bottlers could suffer during a severe global economic downturn, as this would put pressure on consumer spending. Meanwhile, HSBC and AstraZeneca may fall foul of regulatory changes in China, especially if trade tensions with the US worsen at some point. Finally, most of Airtel Africa's revenue is collected in local African currencies, but it's reported in US dollars, exposing the company to currency risk. Nevertheless, adding these stocks to an ISA would make it truly global, with vast exposure to Europe, America, Africa, and Asia. The post 5 top FTSE 100 stocks offering plenty of global growth for an ISA appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool HSBC Holdings is an advertising partner of Motley Fool Money. Ben McPoland has positions in AstraZeneca Plc, Coca-Cola Hbc Ag, and HSBC Holdings. The Motley Fool UK has recommended Airtel Africa Plc, AstraZeneca Plc, and HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
2 days ago
- Associated Press
TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tempus AI, Inc. ('Tempus' or the 'Company') (NASDAQ: TEM) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Tempus securities between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. If you purchased or otherwise acquired Tempus shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 [email protected]
